– PharmaMar (MCE: PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for AplidinR (plitidepsin) for the indication of relapsed and refractory multiple myeloma.

(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

PharmaMar believes that this novel molecule could become part of the therapeutic arsenal available for the treatment of multiple myeloma in Europe.

It is worth noting that the re-examination procedure is handled by the EMA’s CHMP and usually lasts around 4 months. It concludes with either the confirmation of the negative opinion or with the issuing of a new positive opinion by the CHMP.

After finalizing this process of re-examination, the European Commission will be in charge of emitting the final verdict on the Marketing Authorization Application (MAA) for AplidinR (plitidepsin), which could arrive around June or July, 2018.

Media Relations (+34-6387-96215) and Investor Relations (+34-9144-44500)

(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)